Rafferty Asset Management
PTGX icon

Rafferty Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Rafferty Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.93M Sell
46,752
-16,909
-27% -$1.5M 0.02% 360
2025
Q4 		$5.56M Sell
63,661
-11,166
-15% -$914K 0.02% 405
2025
Q3 		$4.97M Sell
74,827
-5,716
-7% -$325K 0.02% 428
2025
Q2 		$4.45M Buy
80,543
+36,286
+82% +$1.74M 0.01% 420
2025
Q1 		$2.14M Sell
44,257
-51,210
-54% -$2.15M 0.01% 559
2024
Q4 		$3.69M Buy
95,467
+5,591
+6% +$244K 0.01% 474
2024
Q3 		$4.04M Buy
89,876
+14,606
+19% +$590K 0.01% 463
2024
Q2 		$2.61M Sell
75,270
-163,938
-69% -$4.8M 0.01% 572
2024
Q1 		$6.92M Buy
239,208
+71,413
+43% +$1.94M 0.03% 379
2023
Q4 		$3.85M Sell
167,795
-182,486
-52% -$3.19M 0.02% 504
2023
Q3 		$5.84M Buy
350,281
+64,822
+23% +$1.26M 0.03% 358
2023
Q2 		$7.88M Buy
285,459
+132,072
+86% +$3.31M 0.04% 287
2023
Q1 		$3.53M Sell
153,387
-141,961
-48% -$2.38M 0.02% 472
2022
Q4 		$3.22M Sell
295,348
-51,587
-15% -$435K 0.03% 468
2022
Q3 		$2.92M Buy
346,935
+32,703
+10% +$309K 0.03% 422
2022
Q2 		$2.49M Buy
314,232
+106,138
+51% +$1.28M 0.02% 425
2022
Q1 		$4.93M Buy
208,094
+42,322
+26% +$1.19M 0.03% 398
2021
Q4 		$5.67M Buy
165,772
+96,642
+140% +$3.05M 0.03% 334
2021
Q3 		$1.23M Buy
69,130
+29,938
+76% +$1.28M 0.01% 759
2021
Q2 		$1.76M Sell
39,192
-36,784
-48% -$1.21M 0.01% 724
2021
Q1 		$1.97M Buy
75,976
+62,102
+448% +$1.57M 0.01% 633
2020
Q4 		$280K Sell
13,874
-14,126
-50% -$304K ﹤0.01% 844
2020
Q3 		$547K Buy
+28,000
New +$525K 0.01% 674

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Rafferty Asset Management's PTGX Position: Q1 2026 in Review

Rafferty Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 27% in Q1 2026, selling an estimated $1.5M and leaving 46,752 shares worth $4.93M. The position accounts for 0.02% of the portfolio, ranked #360.

Rafferty Asset Management first reported a position in PTGX in Q3 2020 and has held it in 23 quarters since. The position peaked at $7.88M in Q2 2023. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Rafferty Asset Management held 46,752 shares of Protagonist Therapeutics worth $4.93M as of Q1 2026.
  • Rafferty Asset Management sold 16,909 Protagonist Therapeutics shares in Q1 2026, an estimated $1.5M.
  • Protagonist Therapeutics made up 0.02% of Rafferty Asset Management's portfolio in Q1 2026, its #360 holding.
  • Rafferty Asset Management first reported a position in Protagonist Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Rafferty Asset Management's Protagonist Therapeutics position peaked at $7.88M in Q2 2023.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.